The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms, and daily life functions; and to learn about the safety of TAK-861. For more information call 877-825-3327 or email medinfoUS@takeda.com

The purpose of this research study is to assess the safety and efficacy of ALKS-2680 compared to placebo, including whether participants taking ALKS-2680 experience greater decrease in sleepiness and a decrease in cataplexy (sudden loss of muscle control) compared to participants taking placebo alone. Contact Alkermes Global Clinical Services by phone at 1-888-235-8008 or email clinicaltrial@alkermes.com to find out more about this study.

Low sodium oxybate has been approved by the US Food and Drug Association (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts the ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this study will use novel tools to determine when an individual is asleep or awake. Contact Clinical Trial Disclosure & Transparency at ClinicalTrialDisclosure@JazzPharma.com or by phone at 215-832-3750 for more information. OR click study number below to see individual sites and contact information.

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). Part 1 will evaluate safety, tolerability, and PK of MK-6552 after administration of ascending doses in a single day to support a dose level decision for Part 2. Part 2 will investigate the PD of MK-6552 after single-day and multiple-day administration. Participants who complete Part 1 and demonstrate that they are able to tolerate at least one dose level of MK-6552 will participate in Part 2. Contact trialsites@merck.com or call 888-577-8839 to find out more about this study. OR click study number below to see individual site contacts.

The purpose of this multicenter double-blind study is to assess efficacy and safety of Pitolisant versus placebo in pediatric narcoleptic patients with or without cataplexy.

About this study: A Study to assess the Long-Term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects with Narcolepsy. This study is an open label extension that will evaluate the long-term efficacy and safety of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS). Click on the NCT link below for contact information by state. OR Contact the Study Director at: SYMPHONYstudy@axsome.com or by phone at 212-332-5061 for more information.

About this study: A Study to Investigate the Effect of Xywav on Sleepiness, Polysomnography, and Functional Outcomes in Participants with Idiopathic Hypersomnia or Narcolepsy. This study is an open label extension that will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic hypersomnia (IH) or narcolepsy. Contact Clinical Trial Disclosure & Transparency at ClinicalTrialDisclosure@JazzPharma.com or by phone at 215-832-3750 for more information.

About this study: A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy. The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy. Contact Clinical Trial Disclosure & Transparency at ClinicalTrialDisclosure@JazzPharma.com or by phone at 215-832-3750 for more information.

About this study: A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions. The is an open label extension that aims to evaluate the safety and tolerability of TAK-861 on participants with type 1 and type 2 narcolepsy from previous parent studies, TAK-861-2001 (NCT05687903) and TAK-861-2002 (NCT05687916). Contact Takeda Contact at medinfoUS@takeda.com or by phone at +1-877-825-3327 for more information.